NIK-250

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407842

CAS#: 1000817-20-8

Description: NIK-250 is a P-glycoprotein inhibitor. NIK250 might be useful in reversing MDR, which often develops during chemotherapy of advanced or hormone-resistant prostatic cancer. NIK250 could also reverse multidrug resistance in human glioma cells. The glioma cell lines were the two MRP-expressing cell lines, T98G and IN500, an MDR1-expressing cell line, CCF-STTG1, and the MRP1 MDR1-non-expressing cell line, IN157.

Chemical Structure

img
NIK-250
CAS# 1000817-20-8
Instruction

Theoretical Analysis

MedKoo Cat#: 407842
Name: NIK-250
CAS#: 1000817-20-8
Chemical Formula: C26H25N3O4S2
Exact Mass: 507.13
Molecular Weight: 507.623
Elemental Analysis: C, 61.52; H, 4.96; N, 8.28; O, 12.61; S, 12.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: NIK-250; NIK 250; NIK250.

IUPAC/Chemical Name: bis(pyridin-4-ylmethyl) 2,6-dimethyl-4-(3-methyl-1,4-dithiin-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate

InChi Key: YEUZKJRCPRSLNP-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H25N3O4S2/c1-16-21(25(30)32-14-19-4-8-27-9-5-19)23(24-18(3)34-12-13-35-24)22(17(2)29-16)26(31)33-15-20-6-10-28-11-7-20/h4-13,23,29H,14-15H2,1-3H3

SMILES Code: O=C(C1=C(C)NC(C)=C(C(OCC2=CC=NC=C2)=O)C1C3=C(C)SC=CS3)OCC4=CC=NC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 507.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tasaki Y, Nakagawa M, Ogata J, Kiue A, Tanimura H, Kuwano M, Nomura Y.
Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug
resistance in etoposide-resistant human prostatic cancer cell line. J Urol. 1995
Sep;154(3):1210-6. PubMed PMID: 7637090.


2: Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, Mori T, Hidaka K, Kuwano M.
Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine
analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br
J Cancer. 1995 Aug;72(2):418-23. PubMed PMID: 7640227; PubMed Central PMCID:
PMC2033970.